[{"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-001", "question": "A 62-year-old man develops painful hepatomegaly, ascites, and jaundice 3 weeks after completing 6 cycles of FOLFOX adjuvant chemotherapy for colon cancer. Total bilirubin is 8.2 mg/dL, ALT 450 U/L, INR 1.8. Liver biopsy shows sinusoidal congestion, hepatocyte necrosis zone 3, and absence of portal inflammation. What is the definitive therapy?", "options": ["A) High-dose methylprednisolone 1 mg/kg/day and diuretics", "B) Defibrotide 25 mg/kg/day IV in divided doses for 21 days", "C) Transjugular intrahepatic portosystemic shunt (TIPS) placement", "D) N-acetylcysteine 150 mg/kg IV bolus then continuous infusion", "E) Urgent liver transplant evaluation"], "answer": "B", "answer_index": 1, "explanation": "Severe sinusoidal obstruction syndrome from oxaliplatin requires defibrotide, which restores thrombomodulin expression and promotes fibrinolysis. TIPS is contraindicated due to diffuse sinusoidal injury; steroids are ineffective. Transplant is reserved for fulminant hepatic failure with encephalopathy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "B", "model_outputs": "The patient presents with a constellation of symptoms (painful hepatomegaly, ascites, jaundice) and laboratory findings (elevated bilirubin, ALT, and INR) occurring 3 weeks after completing FOLFOX chemotherapy. The liver biopsy findings – sinusoidal congestion, zone 3 hepatocyte necrosis, and absence of portal inflammation – are pathognomonic for sinusoidal obstruction syndrome (SOS), also known as hepatic veno-occlusive disease (HVOD). This complication is well-recognized with oxaliplatin-containing chemotherapy regimens like FOLFOX.\n\nNow let's evaluate the treatment options for SOS:\n\nA.  High-dose methylprednisolone 1 mg/kg/day and diuretics: Corticosteroids are generally not recommended for SOS/HVOD as they have not shown efficacy and may increase risks such as infection or bleeding. Diuretics are for symptom management (ascites) but do not treat the underlying SOS.\n\nB.  Defibrotide 25 mg/kg/day IV in divided doses for 21 days: Defibrotide is an agent with anticoagulant and fibrinolytic properties. It has demonstrated efficacy in reducing mortality in severe SOS/HVOD in patients undergoing hematopoietic stem cell transplantation (HSCT), for which it is FDA-approved. Its use in chemotherapy-induced SOS outside of HSCT is also considered, especially in severe cases, due to its mechanism of action targeting endothelial damage and thrombosis within the sinusoids. It is considered a specific therapy for the syndrome.\n\nC.  Transjugular intrahepatic portosystemic shunt (TIPS) placement: TIPS is used to reduce portal pressure in conditions like cirrhosis with portal hypertension. While ascites is present, SOS is caused by obstruction within the sinusoids and hepatic venules, not typically by portal vein thrombosis or cirrhosis. TIPS is not a primary treatment for SOS and can potentially worsen liver function in some cases of SOS.\n\nD.  N-acetylcysteine 150 mg/kg IV bolus then continuous infusion: N-acetylcysteine is primarily an antidote for acetaminophen overdose and is used in certain other toxic liver injuries. It is not indicated for chemotherapy-induced SOS.\n\nE.  Urgent liver transplant evaluation: Liver transplantation is a treatment for irreversible acute liver failure or end-stage liver disease. While severe SOS can lead to acute liver failure, transplant evaluation is typically considered when medical management, including specific therapies like defibrotide, has failed or is not indicated, and the patient is critically ill with no other options. Given that defibrotide is a specific therapy for SOS, it would generally be considered before proceeding to transplant unless the patient is already in immediate life-threatening hepatic failure.\n\nThe question asks for the \"definitive therapy.\" In the context of SOS, defibrotide is a therapy that directly addresses the underlying pathology of sinusoidal obstruction by improving microvascular flow and preventing endothelial damage and thrombosis. It aims to reverse the disease process. Liver transplantation is a definitive treatment for end-stage organ failure but is typically a rescue therapy for SOS when it progresses to irreversible liver failure, not necessarily the initial definitive therapy for SOS itself. Therefore, defibrotide is the most appropriate choice for definitive therapy among the given options for this patient with severe chemotherapy-induced SOS.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-002", "question": "A 48-year-old woman with systemic sclerosis presents with NYHA class IV dyspnea. Right heart catheterization: mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU. Lung biopsy shows diffuse capillary proliferation within alveolar septa without cellular atypia. She fails to respond to epoprostenol and macitentan. Which intervention is associated with the greatest 5-year survival in this rare WHO Group 1' pulmonary hypertension subset?", "options": ["Switch to inhaled treprostinil 54 μg four times daily", "Add selexipag 1600 μg twice daily", "Initiate combination immunosuppression with cyclophosphamide", "Refer for bilateral lung transplantation", "Perform balloon pulmonary angioplasty"], "answer": "D", "answer_index": 3, "explanation": "Pulmonary capillary hemangiomatosis (PCH) is refractory to all PAH-targeted therapies (A, B) and immunosuppression (C). Balloon angioplasty (E) is contraindicated due to diffuse microvascular disease. Bilateral lung transplantation (D) offers the only survival benefit, with 5-year survival approaching 60% in selected patients, far exceeding the <20% survival on medical therapy alone.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed123.jsonl", "pred": "D", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient presents with severe pulmonary arterial hypertension (PAH) likely due to diffuse capillary proliferation (PCH) associated with systemic sclerosis (SSc). Her condition is NYHA class IV and refractory to potent PAH medications (epoprostenol and macitentan). We are looking for the intervention associated with the greatest 5-year survival in this rare subset.\n\n*   Pulmonary Capillary Hemangiomatosis (PCH) is a rare cause of WHO Group 1 PAH characterized by diffuse capillary proliferation. It can occur in association with connective tissue diseases like SSc and tends to be aggressive and poorly responsive to standard PAH therapies.\n*   NYHA Class IV indicates severe symptoms and poor prognosis with existing treatments.\n*   Failure to respond to epoprostenol and macitentan signifies refractory disease, meaning medical management strategies have been exhausted or are insufficient.\n\nLet's evaluate the options:\n\nA.  Switch to inhaled treprostinil: This is another prostacyclin analog. Since the patient has already failed epoprostenol (a potent IV prostacyclin), switching to a different formulation of the same drug class, especially via the inhaled route which may be less effective for severe disease compared to IV, is unlikely to offer the greatest survival benefit.\nB.  Add selexipag: Selexipag is a prostacyclin receptor agonist. While adding another PAH-specific therapy is a consideration, the patient's significant refractory disease and the specific challenges of PCH might limit the benefit compared to more definitive options.\nC.  Initiate combination immunosuppression with cyclophosphamide: Systemic sclerosis is an autoimmune disease, but cyclophosphamide is not a standard treatment for PAH related to PCH. Its use would typically be directed at other manifestations of systemic sclerosis or specific types of connective tissue disease-related PAH, and evidence for its efficacy in PCH is lacking.\nD.  Refer for bilateral lung transplantation: Lung transplantation is considered the definitive treatment for end-stage, refractory PAH when medical therapies fail. For rare and aggressive forms of PAH like PCH that are refractory, lung transplantation can offer a significant survival advantage. Despite potential challenges like recurrence or diagnostic difficulties with PCH, it has been shown to be an effective option for improving long-term survival in selected patients. Given the severity (NYHA IV) and refractory nature of her PAH, transplantation represents the most potent intervention with the potential for the greatest long-term survival.\nE.  Perform balloon pulmonary angioplasty (BPA): BPA is a treatment indicated primarily for chronic thromboembolic pulmonary hypertension (WHO Group 4 PAH), not for PAH related to diffuse capillary proliferation (WHO Group 1).\n\nConsidering the patient's severe, refractory PAH due to PCH within the context of systemic sclerosis, lung transplantation is the most aggressive intervention and offers the best chance for significant long-term survival compared to other options.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-003", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "topics_mapped", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\n\nThe patient presents with subacute neurological deficits, including severe headaches, focal seizures, and left hemiparesis, developing over 3 weeks. Brain MRI reveals multiple ring-enhancing lesions with surrounding edema, a finding that can be seen in various conditions like brain abscesses, toxoplasmosis, cysticercosis, tuberculosis, and tumors.\n\nThe CSF analysis shows lymphocytic pleocytosis (120 cells/μL). This pattern is more suggestive of viral, fungal, mycobacterial, or parasitic infections, or certain inflammatory conditions, rather than a typical pyogenic bacterial meningitis (which often presents with neutrophilic pleocytosis).\n\nCrucially, bacterial, fungal, and mycobacterial cultures are negative. This significantly reduces the likelihood of typical pyogenic brain abscesses or common fungal/mycobacterial infections being the primary target for empiric therapy, although mycobacterial growth can be slow.\n\nThe patient is immunocompetent. In immunocompetent individuals, common causes of ring-enhancing lesions include cysticercosis, neurotuberculosis, certain fungal infections (less common), and tumors. Cerebral toxoplasmosis is much less common in immunocompetent hosts compared to immunocompromised individuals.\n\nConsidering the options:\nA. Liposomal amphotericin B: This is an antifungal agent. It would be considered if fungal infection were strongly suspected, but negative CSF fungal cultures make it less of an immediate empiric choice unless there's high suspicion.\nB. Albendazole plus miltefosine: Albendazole is a broad-spectrum antihelminthic used to treat parasitic infections like neurocysticercosis (caused by *Taenia solium* larvae), which can present with ring-enhancing lesions, seizures, and focal deficits. The gardener occupation *might* suggest potential exposure to parasites. Miltefosine is an antiparasitic prodrug with activity against protozoa (like Leishmania). While the combination is not standard for a single specific diagnosis, it broadly targets parasitic etiologies. Given the negative cultures for other pathogens, parasitic causes such as cysticercosis and potentially toxoplasmosis (though less common in immunocompetent) become more likely.\nC. Vancomycin plus ceftriaxone plus dexamethasone: This is empiric therapy for bacterial meningitis or abscess. The lymphocytic pleocytosis and negative CSF cultures make this less likely to be the single best empiric choice.\nD. Ganciclovir plus foscarnet: These are antiviral agents used for cytomegalovirus (CMV) infections. While CMV can cause encephalitis, multiple ring-enhancing lesions are not its typical presentation.\nE. Voriconazole: Another antifungal agent, primarily used for Aspergillus and Candida infections. Similar to option A, it's less compelling empirically with negative fungal cultures.\n\nGiven the negative CSF cultures for bacteria, fungi, and mycobacteria, and the finding of lymphocytic pleocytosis and ring-enhancing lesions in an immunocompetent individual, parasitic infections (e.g., cysticercosis, toxoplasmosis) become a significant consideration. Option B is the only choice that offers broad antiparasitic coverage. While the combination of albendazole and miltefosine might be atypical, it is the most logical empiric choice if the differential pushes towards parasites after ruling out more common infectious etiologies through negative cultures. The gardener history lends some support to parasitic exposure.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-004", "question": "A 7-year-old girl with McCune-Albright syndrome (confirmed GNAS R201C mutation) presents with premature thelarche, vaginal bleeding, and a growth velocity of 12 cm/year. Bone age is 10 years. Which endocrine intervention specifically targets the underlying pathophysiology of precocious puberty in this condition?", "options": ["GnRH agonist (leuprolide) 7.5 mg IM monthly", "Aromatase inhibitor (letrozole) 2.5 mg daily", "Estrogen receptor antagonist (tamoxifen) 10 mg twice daily", "Progesterone-only contraceptive (medroxyprogesterone) 10 mg daily", "Ketoconazole 200 mg twice daily"], "answer": "B", "answer_index": 1, "explanation": "In McCune-Albright syndrome, precocious puberty results from autonomous ovarian hyperfunction, not central activation. GnRH agonists are ineffective because the process is gonadotropin-independent. Aromatase inhibitors block peripheral estrogen synthesis from autonomous follicular cysts. Tamoxifen is less effective and has more side effects. Progesterone doesn't address estrogen excess. Ketoconazole has significant toxicity.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "B", "model_outputs": "The question asks for the endocrine intervention that specifically targets the underlying pathophysiology of precocious puberty in McCune-Albright syndrome (MAS).\n\nMAS is caused by activating mutations in the GNAS gene, leading to constitutive activation of signal transduction pathways, most commonly the cAMP pathway. In the gonads, this results in autonomous activation of follicular development and steroidogenesis, leading to the production of estrogen and androgens, which are then converted to estrogen. This peripheral source of estrogen bypasses the normal hypothalamic-pituitary-gonadal (HPG) axis and causes precocious puberty.\n\nLet's evaluate the options:\nA. GnRH agonist (leuprolide): GnRH agonists suppress the pituitary's release of LH and FSH, thereby reducing gonadal steroid production. This is the standard treatment for *central* precocious puberty, where the HPG axis is activated prematurely. However, in MAS, the gonadal overactivity is typically autonomous and independent of GnRH stimulation. Therefore, GnRH agonists are not the primary or most specific treatment for MAS-related precocious puberty, although they may be used in some cases.\n\nB. Aromatase inhibitor (letrozole): Aromatase is the enzyme responsible for the final step in estrogen synthesis, converting androgens (androstenedione and testosterone) to estrogens (estrone and estradiol). Inhibiting aromatase directly reduces estrogen levels. Since the precocious puberty in MAS is driven by excess estrogen production from autonomously stimulated ovaries, an aromatase inhibitor specifically targets this hyperestrogenism and is considered a key therapeutic option for MAS-associated precocious puberty.\n\nC. Estrogen receptor antagonist (tamoxifen): Tamoxifen blocks the action of estrogen at its receptors. While it can manage some symptoms of estrogen excess, it does not reduce the excessive production of estrogen from the ovaries. It is not a primary treatment for targeting the pathophysiology of overproduction.\n\nD. Progesterone-only contraceptive (medroxyprogesterone): Progestins like medroxyprogesterone can suppress ovulation and cyclic bleeding, and are sometimes used to manage menstrual irregularities or bleeding in precocious puberty. However, they do not reduce the underlying estrogen production that drives the pubertal development.\n\nE. Ketoconazole: Ketoconazole is an imidazole antifungal that also inhibits several key enzymes in steroidogenesis, including CYP17A1 and CYP11A1, thereby reducing the synthesis of both androgens and estrogens. It can be useful in managing steroid excess conditions. However, it is a less specific inhibitor of steroidogenesis compared to aromatase inhibitors and can have significant side effects (e.g., hepatotoxicity). While it can reduce estrogen levels, aromatase inhibitors (like letrozole) are more specifically targeted at reducing estrogen synthesis, which is the direct cause of the pubertal signs.\n\nConsidering the options, the intervention that most specifically targets the underlying pathophysiology of peripheral hyperestrogenism causing precocious puberty in MAS is an aromatase inhibitor, which directly reduces estrogen synthesis.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-005", "question": "A 35-year-old presents with refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. What is the optimal insulin dosing and monitoring frequency?", "options": ["0.5-1 unit/kg/hr; check glucose every 2 hours", "1-10 units/kg/hr; check glucose every hour", "0.1-0.5 units/kg/hr; check potassium every 4 hours", "5-20 units/kg/hr; check lactate every 2 hours", "2-5 units/kg/hr; check pH every 4 hours"], "answer": "B", "answer_index": 1, "explanation": "HIET for severe calcium channel blocker overdose requires supraphysiologic insulin doses of 1-10 units/kg/hr to overcome insulin resistance and maximize myocardial glucose uptake. Blood glucose must be monitored hourly to maintain euglycemia (150-200 mg/dL) with concurrent dextrose infusion. Lower doses are ineffective. Doses exceeding 10 units/kg/hr are not standard practice. Potassium and pH are monitored but glucose is the critical parameter.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Emergency Medicine", "abms_specialty": "Emergency Medicine", "abms_source": "topics_mapped", "source_label_raw": "Emergency Medicine", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed125", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed125.jsonl", "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient presents with refractory shock and bradycardia due to a significant verapamil overdose. High-dose insulin euglycemic therapy (HIET) is the management strategy.\nFor calcium channel blocker (CCB) toxicity managed with HIET, the insulin infusion dose typically starts at 1 unit/kg/hr and can be titrated up to 10 units/kg/hr or higher as needed based on hemodynamic response and glucose levels. The range of 1-10 units/kg/hr is commonly cited for effective treatment of severe CCB overdose.\nCrucially, with high-dose insulin infusions, frequent glucose monitoring is essential to prevent and detect hypoglycemia. Hourly glucose checks are standard practice during HIET.\nLet's evaluate the options:\nA. 0.5-1 unit/kg/hr; check glucose every 2 hours: The dosing range is on the lower side for refractory shock, and checking glucose every 2 hours is less frequent than recommended.\nB. 1-10 units/kg/hr; check glucose every hour: This dosing range is appropriate for severe CCB toxicity, and hourly glucose monitoring is critical for safety and efficacy.\nC. 0.1-0.5 units/kg/hr; check potassium every 4 hours: This dosing range is too low for severe CCB overdose.\nD. 5-20 units/kg/hr; check lactate every 2 hours: While high doses are used, starting at 5-20 units/kg/hr might be aggressive initially without titration. Monitoring lactate is important for shock but not the primary monitoring for insulin therapy itself.\nE. 2-5 units/kg/hr; check pH every 4 hours: This is a reasonable dosing range, but checking pH is not the primary indicator for insulin dosing or safety monitoring in HIET.\n\nOption B provides the most appropriate dosing range and frequency for monitoring glucose, which is essential for the safe and effective use of HIET in this severe verapamil overdose.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-006", "question": "A 30-year-old G2P1 at 32 weeks gestation presents with fetal hydrops and mirror syndrome. Which pathophysiologic mechanism best explains her severe preeclampsia-like features?", "options": ["Massive fetomaternal hemorrhage causing maternal anemia", "Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)", "Maternal antibody production against fetal Rh antigens", "Amniotic fluid embolism triggering systemic inflammation", "Mirror syndrome is a misdiagnosis; this is atypical HELLP"], "answer": "B", "answer_index": 1, "explanation": "Mirror syndrome involves placental edema that mechanically compromises uteroplacental perfusion and releases anti-angiogenic factors like sFlt-1, creating a preeclampsia phenotype. Resolution occurs within 48 hours of delivery or fetal therapy that reduces hydrops.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Obstetrics and Gynecology", "abms_specialty": "Obstetrics and Gynecology", "abms_source": "topics_mapped", "source_label_raw": "obstetrics", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed126.jsonl", "pred": "B", "model_outputs": "The patient presents with fetal hydrops and mirror syndrome, along with severe preeclampsia-like features. Mirror syndrome (also known as triple edema) is characterized by maternal edema, placental edema, and fetal hydrops. This condition is strongly associated with placental pathology and is often considered a severe form of preeclampsia or a closely related entity. Preeclampsia is fundamentally a disease of endothelial dysfunction driven by an imbalance of angiogenic factors. The placenta, particularly when dysregulated, releases anti-angiogenic factors, such as soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng). These factors are thought to antagonize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), leading to widespread endothelial activation and dysfunction in the maternal circulation. This endothelial dysfunction manifests as hypertension, proteinuria, and edema, which are the hallmark features of preeclampsia. In mirror syndrome, the extensive placental edema and dysfunction likely contribute significantly to the release of these anti-angiogenic factors, thus explaining the severe preeclampsia-like features in the mother. Fetal hydrops can arise from several causes, including severe placental insufficiency, anemia, or cardiac problems, all of which can be exacerbated by the severe placental insult seen in mirror syndrome.\n\nLet's analyze why other options are less suitable:\nA. Massive fetomaternal hemorrhage causing maternal anemia: While fetomaternal hemorrhage can cause maternal anemia, it doesn't directly explain fetal hydrops and mirror syndrome with prominent preeclampsia-like features. The primary mechanism involves placental factors.\nC. Maternal antibody production against fetal Rh antigens: Rh alloimmunization leads to fetal hemolytic disease and hydrops. However, it typically does not cause severe preeclampsia-like features or mirror syndrome in the mother.\nD. Amniotic fluid embolism triggering systemic inflammation: Amniotic fluid embolism is an acute, catastrophic event with sudden cardiopulmonary collapse and DIC, not typically presenting as mirror syndrome with evolving preeclampsia-like features.\nE. Mirror syndrome is a misdiagnosis; this is atypical HELLP: Mirror syndrome is a recognized entity, and while it shares features with preeclampsia and HELLP, it is not necessarily a misdiagnosis. The question asks for the pathophysiologic mechanism explaining the features, and option B provides this directly for the maternal preeclampsia-like symptoms.\n\nTherefore, the release of sFlt-1 from the edematous and dysregulated placenta is the most fitting pathophysiologic mechanism for the severe preeclampsia-like features observed in this patient with fetal hydrops and mirror syndrome.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-007", "question": "A 35-year-old male in a personal injury lawsuit reports severe chronic pain despite normal examinations and imaging. He is observed to be inconsistent in his symptom presentation between evaluations. Which specific criterion best distinguishes malingering from factitious disorder in this scenario?", "options": ["Presence of secondary gain", "Intentional production of symptoms", "Lack of insight into psychological factors", "Symptoms are under voluntary control", "Absence of medical explanation"], "answer": "A", "answer_index": 0, "explanation": "Both malingering and factitious disorder involve intentional symptom production. The key distinction is motivation: malingering seeks external reward (money, avoiding work), while factitious disorder seeks the 'sick role' for psychological needs. Both have insight and voluntary control. Absence of medical explanation is common to both somatic symptom disorders.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "abms_specialty": "Psychiatry", "abms_source": "target_topic", "source_label_raw": "Psychiatry", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-020", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "A", "model_outputs": "NOT FOR CLINICAL USE.\nThe question asks for the specific criterion that best distinguishes malingering from factitious disorder in the given scenario.\n\nLet's analyze the key differences:\n*   Malingering: Intentional production of false or grossly exaggerated symptoms motivated by external incentives (secondary gain). Examples include financial compensation, avoiding duty, or obtaining drugs. The scenario mentions a personal injury lawsuit, which strongly suggests the potential for secondary gain.\n*   Factitious Disorder: Intentional production of feigned or exaggerated physical or psychological signs or symptoms motivated by a desire to assume the \"sick role\" (primary gain). There is no obvious external incentive.\n\nNow let's evaluate the options:\nA. Presence of secondary gain: Secondary gain is the defining external incentive in malingering. In this scenario, the personal injury lawsuit provides a clear context where secondary gain (e.g., financial compensation) is a likely motivator. If secondary gain is present or strongly suspected, malingering is indicated. Factitious disorder is specifically *not* associated with external incentives; the motivation is internal (assuming the sick role). Therefore, the presence of secondary gain is a crucial distinguishing factor.\n\nB. Intentional production of symptoms: Both malingering and factitious disorder involve the intentional production of symptoms. This criterion does not distinguish between them.\n\nC. Lack of insight into psychological factors: This is more characteristic of somatic symptom disorder or conversion disorder, where symptoms are not intentionally produced. While individuals with factitious disorder might not fully understand the underlying psychological need driving their behavior, the core distinction between malingering and factitious disorder lies in the motivation for symptom production, not necessarily insight into psychological factors.\n\nD. Symptoms are under voluntary control: In both malingering and factitious disorder, the symptoms are intentionally produced and thus under voluntary control. This criterion does not distinguish between them.\n\nE. Absence of medical explanation: The scenario states normal examinations and imaging, indicating an absence of a clear medical explanation for the *reported* severity of symptoms. However, this is common in both malingering (where symptoms are feigned) and factitious disorder (where symptoms are feigned or exaggerated). Therefore, it does not reliably distinguish between the two.\n\nIn the context of a personal injury lawsuit, the presence or likelihood of secondary gain is the most direct and best distinguishing criterion for inferring malingering over factitious disorder.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-008", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "abms_specialty": "Neurology", "abms_source": "topics_mapped", "source_label_raw": "Neurology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "C", "model_outputs": "The patient presents with a progressive neurological syndrome characterized by significant sleep dysfunction, including dream enactment (REM sleep behavior disorder), nocturnal stridor, and daytime somnolence. He also has gait instability, mild cognitive decline, and mild cerebellar atrophy on MRI.\n\nLet's evaluate the options:\n\nA.  Anti-Hu antibody: Typically associated with paraneoplastic syndromes, often from small cell lung cancer. The clinical presentation usually includes sensory neuronopathy, ataxia, and brainstem or limbic encephalitis. REM sleep behavior disorder (RBD) is not a typical feature.\n\nB.  Anti-Yo antibody: Primarily associated with paraneoplastic cerebellar degeneration, usually seen in women with gynecological cancers. It causes rapid progressive ataxia. The patient is male, and RBD is not characteristic.\n\nC.  Anti-IgLON5 antibody: This antibody is associated with a distinct neurological syndrome characterized by prominent sleep disturbances, including RBD, obstructive sleep apnea, insomnia, and non-REM parasomnias. Other features can include progressive supranuclear gaze palsy, ataxia, parkinsonism, bulbar dysfunction (dysphagia, stridor), and cognitive impairment. The age group (older adults) and constellation of symptoms, including sleep disorders, gait instability, cognitive decline, and potentially brainstem/cerebellar involvement (suggested by atrophy and stridor), strongly align with anti-IgLON5-associated encephalitis.\n\nD.  Anti-Ma2 antibody: Associated with paraneoplastic limbic and brainstem encephalitis, often linked to testicular germ cell tumors. While it can cause amnesia, movement disorders, and ataxia, RBD is not a primary feature.\n\nE.  Anti-NMDA receptor antibody: While it can cause a broad range of neurological and psychiatric symptoms, including movement disorders and cognitive decline, it is more common in younger individuals, particularly women. RBD is not a typical core feature, and the specific combination of sleep dysfunction, stridor, gait instability, and cerebellar atrophy is less characteristic of this antibody compared to anti-IgLON5.\n\nGiven the prominent sleep dysfunction (RBD, stridor, somnolence) combined with gait instability, cognitive decline, and cerebellar atrophy in an older male, anti-IgLON5 antibody is the most likely association.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-009", "question": "A 2-month-old infant with congenital lymphocytic choriomeningitis virus (LCMV) infection presents with chorioretinitis, hydrocephalus, and periventricular calcifications. Which neuroimaging finding best distinguishes LCMV from congenital cytomegalovirus infection?", "options": ["Periventricular calcifications", "Cortical malformations", "Cerebellar hypoplasia", "Temporal lobe cysts", "Lissencephaly"], "answer": "C", "answer_index": 2, "explanation": "While both LCMV and CMV can cause periventricular calcifications, LCMV characteristically causes severe cerebellar hypoplasia due to selective infection of the external granular layer cells. CMV more commonly causes cortical malformations, temporal lobe cysts, and lissencephaly. This distinction is critical for prognosis and genetic counseling, as LCMV has a higher risk of severe neurodevelopmental disability.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "B", "model_outputs": "The question asks to identify a neuroimaging finding that best distinguishes congenital Lymphocytic Choriomeningitis Virus (LCMV) infection from congenital Cytomegalovirus (CMV) infection in an infant presenting with chorioretinitis, hydrocephalus, and periventricular calcifications.\n\nLet's analyze the typical neuroimaging findings for each infection:\n\n*   Congenital Cytomegalovirus (CMV) Infection: This is the most common congenital viral infection. Its hallmark neuroimaging findings include:\n    *   Periventricular calcifications (often dense, punctate, or nodular) - This is a classic feature.\n    *   Hydrocephalus and ventriculomegaly.\n    *   Microcephaly.\n    *   Cortical malformations (e.g., polymicrogyria, schizencephaly).\n    *   Cerebellar hypoplasia.\n    *   Periventricular cysts.\n    *   Temporal lobe involvement.\n\n*   Congenital Lymphocytic Choriomeningitis Virus (LCMV) Infection: This is a rarer congenital infection. Its neuroimaging findings typically include:\n    *   Hydrocephalus.\n    *   Global cerebral atrophy.\n    *   Cortical malformations, often described as diffuse, including polymicrogyria and lissencephaly.\n    *   Cerebellar hypoplasia.\n    *   Calvarial defects.\n    *   Periventricular calcifications are usually absent or minimal.\n\nNow let's evaluate the given options in the context of distinguishing LCMV from CMV:\n\nA.  Periventricular calcifications: The question states the infant with LCMV presents with periventricular calcifications. However, these are classically associated with CMV and are typically absent or minimal in LCMV. Therefore, the *presence* of periventricular calcifications generally points more towards CMV, making it not the best distinguishing feature *for* LCMV from CMV.\n\nB.  Cortical malformations: Both LCMV and CMV can cause cortical malformations. However, literature often highlights that congenital LCMV infection is typically associated with more diffuse and profound cortical malformations, including polymicrogyria and lissencephaly, reflecting a widespread disruption of neuronal migration. CMV can also cause polymicrogyria and schizencephaly, but the pattern and severity can differ, and it's more strongly associated with periventricular lesions. The general category of \"cortical malformations\" represents a key area of difference in the pathogenesis and resulting brain damage.\n\nC.  Cerebellar hypoplasia: This finding can be present in both congenital LCMV and CMV infections, so it is not a strong distinguishing feature.\n\nD.  Temporal lobe cysts: Temporal lobe involvement and cysts are more characteristic features of congenital CMV infection. Its presence would favor CMV over LCMV.\n\nE.  Lissencephaly: Lissencephaly is a severe type of cortical malformation (agyria or pachygyria) indicating profound disruption of neuronal migration. It is frequently described as a prominent feature of congenital LCMV infection. While severe cortical malformations can occur with other insults, diffuse lissencephaly is a significant finding that helps differentiate LCMV from CMV, which more commonly causes polymicrogyria and schizencephaly.\n\nComparing options B and E: Lissencephaly (E) is a specific and severe type of cortical malformation. Option B (Cortical malformations) is a broader category. Many comparative studies emphasize that LCMV tends to cause more diffuse and extensive cortical malformations, often including lissencephaly. Given that CMV also causes cortical malformations (like polymicrogyria and schizencephaly), the presence of diffuse cortical disruption, particularly severe forms like lissencephaly, is a key differentiator pointing towards LCMV. Between the general category and a specific severe manifestation, the more specific severe outcome that is characteristic of LCMV's impact on cortical development is often used to distinguish it. Literature often points to diffuse cerebral atrophy and severe cortical malformations including lissencephaly as hallmarks of LCMV.\n\nHowever, in many comparative neuroimaging descriptions, the contrast is drawn between CMV's periventricular calcifications and LCMV's diffuse cortical damage, which encompasses various malformations. \"Cortical malformations\" (B) as a general characteristic of disturbed gyration is often cited as a key difference from CMV's typical periventricular involvement. If the infant already has periventricular calcifications (favoring CMV), then the presence of significant diffuse cortical malformations would be the feature suggesting LCMV.\n\nConsidering standard radiological descriptions and comparative reviews, the broad category of \"Cortical malformations\" (B) represents the overall differing pattern of cerebral insult. LCMV directly impacts cortical development more diffusely, leading to various malformations, whereas CMV's primary impact is often periventricular, though it can also cause cortical abnormalities. Therefore, the general presence and pattern of cortical malformations are often highlighted as a distinguishing feature.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-010", "question": "A 2-month-old infant presents with heart failure, mitral regurgitation, and echocardiographic finding of retrograde flow in a dilated left coronary artery during diastole. Which additional echocardiographic finding is pathognomonic for anomalous left coronary artery from pulmonary artery (ALCAPA)?", "options": ["Left ventricular dilation", "Papillary muscle dysfunction", "Septal wall motion abnormalities", "Coronary artery collaterals with 'seagull' sign", "Right coronary artery dilation"], "answer": "D", "answer_index": 3, "explanation": "In ALCAPA, extensive intercoronary collaterals develop with characteristic bidirectional flow seen on color Doppler as a 'seagull' sign. While LV dilation, papillary muscle dysfunction, and RCA dilation are seen, they are not pathognomonic. The seagull sign represents collaterals from RCA to LCA with flow reversal into PA, which is diagnostic of ALCAPA.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-013", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "D", "model_outputs": "The question asks for an additional echocardiographic finding that is pathognomonic for anomalous left coronary artery from pulmonary artery (ALCAPA), given that the infant presents with heart failure, mitral regurgitation, and retrograde flow in a dilated left coronary artery during diastole.\n\nLet's analyze the findings associated with ALCAPA:\nIn ALCAPA, the left coronary artery originates from the pulmonary artery instead of the aorta. This results in the left ventricle being perfused with unsaturated blood from the pulmonary artery. This leads to myocardial ischemia, dysfunction, and infarction of the left ventricle, causing heart failure and mitral regurgitation (often due to papillary muscle dysfunction).\n\nThe finding of retrograde flow in the left coronary artery during diastole is a critical clue. During diastole, aortic pressure drops. If the left coronary artery is receiving blood from the systemic circulation (either directly from the aorta or via collaterals), and the pulmonary artery diastolic pressure is low, blood can flow retrogradely from the aorta back into the LCA system. This implies the LCA is not adequately perfused solely by the pulmonary artery.\n\nWe need an *additional* finding that is *pathognomonic* for ALCAPA. Pathognomonic means that the finding is uniquely characteristic of the disease.\n\nLet's evaluate the options:\nA.  Left ventricular dilation: While common in ALCAPA due to chronic ischemia and heart failure, LV dilation is not pathognomonic as it can be seen in many other cardiac conditions.\nB.  Papillary muscle dysfunction: This is a consequence of LV ischemia and is frequently seen in ALCAPA, leading to mitral regurgitation. However, it is also seen in other ischemic heart diseases and cardiomyopathies.\nC.  Septal wall motion abnormalities: These indicate localized myocardial dysfunction or infarction. Any area of the myocardium can develop wall motion abnormalities due to ischemia from various causes, so this is not pathognomonic for ALCAPA.\nD.  Coronary artery collaterals with 'seagull' sign: In ALCAPA, to compensate for the poor perfusion of the left ventricle, collateral circulation often develops. These collaterals typically arise from the right coronary artery (RCA) or from the aorta. The \"seagull sign\" refers to the appearance on echocardiography of dilated coronary arteries (especially the RCA and its branches) and extensive collateral vessels supplying the ischemic territory of the left ventricle. This robust collateralization is a compensatory mechanism that allows infants with ALCAPA to survive beyond the neonatal period. The visualization and description of this specific collateral network are highly characteristic of ALCAPA.\nE.  Right coronary artery dilation: The RCA often dilates significantly in ALCAPA because it becomes a major source of collateral flow to the left ventricle. While RCA dilation is a common finding and part of the picture described in option D, the dilation of the RCA alone might not be considered as pathognomonic as the visualization of the entire collateral pattern (the seagull sign). The seagull sign encompasses the dilation of the vessels and the demonstration of their function as collaterals.\n\nConsidering the definition of pathognomonic, the 'seagull sign', representing the development and visualization of a significant coronary collateral network to perfuse the ischemic left ventricle, is the most specific additional finding among the choices presented that strongly points to ALCAPA. The retrograde flow in LCA diastole suggests systemic supply, and the seagull sign visualizes a major component of this supply (collaterals, often from the RCA).\n\nThe final answer is $\\boxed{D}$."}]